Key Takeaways
- The market is rallying into the holiday season, driven by expectations of Federal Reserve rate cuts.
- Big tech leadership is diversifying beyond NVIDIA, with Apple and Alphabet gaining investor attention.
- Portfolio adjustments are recommended, favoring broader market participation and private investments over concentrated big-cap tech.
- A multi-million dollar 'wrench attack' highlights significant security risks in cryptocurrency self-custody.
- Eli Lilly faces emerging competition in the rapidly expanding obesity drug market from Amgen.
Deep Dive
- Major market averages are on a four-day streak, with the S&P 500 up over 3% heading into Thanksgiving week.
- Traders debate the possibility of a year-end rally, noting the market's strong rebound from recent lows.
- The market's upward trend is significantly influenced by expectations of Federal Reserve rate cuts.
- JPMorgan analysts indicate a higher probability of rate cuts, impacting overall market sentiment and stock performance.
- A wealth management director advises scaling back big-cap technology stocks due to concentration risks.
- Clients are encouraged to adopt a more equal-weighted approach, diversifying beyond the seven stocks driving S&P 500 gains.
- The strategy favors generic U.S. large-cap companies with potential to leverage AI, rather than exclusively AI-focused firms.
- Apple's recent all-time highs are partly attributed to money flows and unpriced AI potential, raising valuation concerns at 32 times next year's earnings.
- Breaking news reported a shooting in Washington D.C. near the White House.
- Two National Guardsmen were shot and are in critical condition, correcting earlier reports of fatalities.
- The suspect was apprehended after being shot by other Guardsmen; investigators believe it was a single shooter.
- Secretary of Defense Pete Hegseth called for an additional 500 National Guardsmen to be sent to D.C.
- Deutsche Bank reaffirmed a buy rating on Oracle, citing its business with OpenAI and role in deploying AI infrastructure.
- Oracle shares jumped 4% following the news but remain down over 37% from their September peak.
- Analysts debated Oracle's valuation, describing it as a 'battleground stock' with noted negative free cash flow.
- Some analysts questioned Oracle's potential compared to Alphabet, observing volatile price action.
- An investor lost $11 million in Bitcoin and Ethereum in a targeted heist, described as a 'wrench attack'.
- The intruder gained access to digital keys through physical threats, highlighting risks in self-custody.
- Despite the security incident, a trader noted Bitcoin's ability to recover from a 15% pullback as encouraging.
- Growing institutional and retail investor interest, possibly influenced by new ETFs, supports Bitcoin's resilience.
- The Dow, S&P, and NASDAQ showed gains ahead of the Thanksgiving break, with several companies hitting new highs.
- Lowe's, Travelers, GM, and Walmart were among the companies reaching new highs.
- Boeing was debated: one trader expected recovery due to production ramp-ups, another cited valuation concerns relative to 2018 earnings.
- Gold is up 58% year-to-date, approaching all-time highs, and is considered an essential alternate investment.
- Eli Lilly's stock is up 43% year-to-date in the competitive obesity drug market.
- Amgen emerged as a new competitor with upcoming data on its monthly obesity shot, Maritide.
- Positive Maritide data could cause a short-term dip in Eli Lilly's stock, but Lilly and Novo Nordisk are expected to dominate long-term.
- The US obesity drug market is forecasted to grow from $20 billion to $150 billion by 2030.
- GLP-1 drugs are described as transformative not just for obesity, but for managing chronic conditions.
- These drugs are projected to significantly reduce overall healthcare costs.
- A recent ICER symposium suggested that drugs like ZEPBO could be cost-saving for the healthcare system.
- One trader maintains a positive outlook on Eli Lilly, holding a significant portfolio allocation and selling upside calls.